[Antifungal therapy update: new drugs and medical uses]

Jesús Fortún1

  • 1Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España. fortunabete@gmail.com

Insights

Rising fungal infections necessitate new antifungal drugs. This review updates clinical evidence on new agents like micafungin, anidulafungin, and posaconazole for treating serious Candida and Aspergillus infections.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Increasing rates of invasive fungal infections and associated mortality highlight the urgent need for novel antifungal agents.
  • Candida spp. and Aspergillus spp. are primary pathogens in immunocompromised and critically ill patients, but emerging fungi also pose significant threats.
  • Antifungal therapy is becoming more complex with the introduction of new agents, requiring updated clinical guidance.

Purpose of the Study:

  • To provide an evidence-based update on the clinical efficacy, pharmacokinetics, safety, and dosing of antifungal drugs.
  • To review the management of infections caused by Candida spp., Aspergillus spp., Cryptococcus spp., Zygomycetes, Scedosporium spp., and Fusarium spp.
  • To discuss the role of newly introduced antifungal agents: micafungin, anidulafungin, and posaconazole.

Main Methods:

  • Systematic review of the latest scientific evidence.
  • Analysis of clinical trial data and pharmacokinetic studies.
  • Evaluation of safety profiles and dosing recommendations for various antifungal drugs.

Main Results:

  • Micafungin, anidulafungin, and posaconazole represent significant advances in antifungal armamentarium.
  • Updated data on the efficacy and safety of established and novel antifungal agents across a spectrum of fungal pathogens.
  • Guidance on rational, early systemic antifungal treatment integrating diagnostic and therapeutic strategies.

Conclusions:

  • New antifungal agents offer improved therapeutic options for complex fungal infections.
  • Evidence-based management of fungal infections requires continuous updates on drug efficacy, safety, and dosing.
  • Optimizing antifungal therapy is crucial for reducing morbidity and mortality in vulnerable patient populations.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...